ST Xiangxue: TAEST1901 injection obtained clinical trial approval.

ST Xiangxue announced on the evening of May 15th that its subsidiary Xiangxue Life Science has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. Xiangxue Life Science's new drug clinical registration application for TAEST1901 injection has been granted clinical trial approval, with indications for the treatment of late-stage gastric cancer with the genotype HLA-A*02:01 and positive expression of tumor antigen AFP.